Aptiom and Urticaria - a phase IV clinical study of FDA data

Summary:

Urticaria is reported as a side effect among people who take Aptiom (eslicarbazepine acetate), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Keppra, and have Seizures.

The phase IV clinical study analyzes which people have Urticaria when taking Aptiom. It is created by eHealthMe based on reports of 2,380 people who have side effects when taking Aptiom from the FDA, and is updated regularly.

What is Aptiom?

Aptiom has active ingredients of eslicarbazepine acetate. eHealthMe is studying from 2,404 Aptiom users. Check the latest studies of Aptiom.

What is Urticaria?

Urticaria (rash of round, red welts on the skin that itch intensely) is found to be associated with 2,622 drugs and 2,952 conditions by eHealthMe. Check the latest studies of Urticaria.

On Jul, 14, 2026

2,380 people reported to have side effects when taking Aptiom.
Among them, 14 people (0.59%) have Urticaria.

Among these 14 people:

How long have people been on Aptiom when they have Urticaria? *

What is the gender of people who have Urticaria when taking Aptiom? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Urticaria when taking Aptiom? *

What are other drugs people take besides Aptiom? *

What are other side effects people have besides Urticaria? *

Itching: 6 people, 42.86%
Rashes (redness): 4 people, 28.57%
Hypersensitivity: 3 people, 21.43%
Loss Of Consciousness: 2 people, 14.29%
Drug Ineffective: 2 people, 14.29%
Peripheral Swelling: 2 people, 14.29%
Dyspnea (difficult or laboured breathing): 2 people, 14.29%
Head Injury: 1 person, 7.14%
Headache (pain in head): 1 person, 7.14%
Haemorrhage (bleeding): 1 person, 7.14%

What are the existing conditions these people have? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 7 people, 50.00%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 14.29%
Brain Neoplasm Malignant (brain cancer tumour): 2 people, 14.29%
Tri-Iodothyronine Decreased: 1 person, 7.14%
Sinusitis (inflammation of sinus): 1 person, 7.14%
Immunodeficiency Common Variable: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Aptiom and have Urticaria?

- Check whether Urticaria is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aptiom:

Aptiom (2,404 reports)

Urticaria treatments and more:

Urticaria (173,777 reports)

Browse all side effects of Aptiom:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urticaria:

Urticaria (2,622 drugs)

Browse all the conditions that are associated with Urticaria:

Urticaria (2,952 conditions)

Related publications that referenced our studies

Sharma SP, Muggia F, "Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case report", ecancermedicalscience, 2016 Jan .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .
Sharma SP, Muggia F, "Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case report", ecancermedicalscience, 2016 Jan .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on eslicarbazepine acetate (the active ingredients of Aptiom) and Aptiom (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.